In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GenMark Diagnostics nets $25.7mm through its IPO

Executive Summary

GenMark Diagnostics Inc. (formerly Osmetech; molecular diagnostic systems) has completed its initial public offering. It netted $25.7mm through the sale of 4.6mm common shares at $6 each, lower than the $8-10 range the company had expected.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Biosensors
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register